Pomerantz Law Firm Launches Investigation into Surgery Partners, Inc. for Potential Investor Claims
On November 20, 2025, the Pomerantz Law Firm announced it is actively investigating claims on behalf of investors of Surgery Partners, Inc. (NASDAQ: SGRY). The firm is collecting information to determine whether Surgery Partners, along with certain executives or directors, engaged in securities fraud or other unlawful business practices. This development comes after Surgery Partners issued a troubling press release on November 10, 2025, detailing their financial results for the third quarter.
During that call, the company lowered its full-year revenue guidance, estimating between $3.275 billion and $3.3 billion, with an adjusted EBITDA range of $535 million to $540 million. The management attributed these reductions to several critical factors including delays in capital deployment, loss of earnings from divestitures related to ambulatory surgical centers, and a very cautious outlook on the volume and payer mix for the upcoming fourth quarter. As a result of this disappointing announcement, Surgery Partners' stock price saw a significant decline, dropping by $5.47 per share, translating to a 25.42% decline, ultimately closing at $16.04 on the same day.
Pomerantz LLP, recognized as one of the foremost law firms specializing in corporate, securities, and antitrust class actions, is encouraging investors affected by these developments to get in touch with them for more information or to join the class action. With a legacy spanning over 85 years, the firm has garnered a reputation for advocating on behalf of victims of securities fraud and corporate misconduct, underpinned by their founder, Abraham L. Pomerantz, often referred to as the dean of the class action bar.
This investigation isn’t just an isolated case; it reflects a broader concern within the financial markets where investors must remain vigilant against potential fraudulent actions by corporate leadership. Pomerantz has previously secured numerous multimillion-dollar settlements for their clients, reinforcing the firm's commitment to protecting investor rights.
If you believe that you have been misled or suffered losses as a result of Surgery Partners' actions, it is crucial to reach out to Danielle Peyton at Pomerantz LLP via their contact number or email as provided. Participating in this investigation may provide you with some recourse in light of the stock drop and the company's revised guidance.
With ongoing scrutiny, the outcome of Pomerantz’s investigation may have significant implications not only for Surgery Partners but for the broader arena of investor relations in publicly traded companies. As investors navigate these complexities, the importance of transparency and ethical corporate governance has never been more paramount.
This case exemplifies just how important it is for investors to remain informed and proactive about their investments, especially when financial forecasts appear grim. As the situation unfolds, stakeholders will undoubtedly be watching closely to see how Surgery Partners and its executives respond to these challenges, and whether they take the necessary steps to restore investor confidence in their operations again.
During that call, the company lowered its full-year revenue guidance, estimating between $3.275 billion and $3.3 billion, with an adjusted EBITDA range of $535 million to $540 million. The management attributed these reductions to several critical factors including delays in capital deployment, loss of earnings from divestitures related to ambulatory surgical centers, and a very cautious outlook on the volume and payer mix for the upcoming fourth quarter. As a result of this disappointing announcement, Surgery Partners' stock price saw a significant decline, dropping by $5.47 per share, translating to a 25.42% decline, ultimately closing at $16.04 on the same day.
Pomerantz LLP, recognized as one of the foremost law firms specializing in corporate, securities, and antitrust class actions, is encouraging investors affected by these developments to get in touch with them for more information or to join the class action. With a legacy spanning over 85 years, the firm has garnered a reputation for advocating on behalf of victims of securities fraud and corporate misconduct, underpinned by their founder, Abraham L. Pomerantz, often referred to as the dean of the class action bar.
This investigation isn’t just an isolated case; it reflects a broader concern within the financial markets where investors must remain vigilant against potential fraudulent actions by corporate leadership. Pomerantz has previously secured numerous multimillion-dollar settlements for their clients, reinforcing the firm's commitment to protecting investor rights.
If you believe that you have been misled or suffered losses as a result of Surgery Partners' actions, it is crucial to reach out to Danielle Peyton at Pomerantz LLP via their contact number or email as provided. Participating in this investigation may provide you with some recourse in light of the stock drop and the company's revised guidance.
With ongoing scrutiny, the outcome of Pomerantz’s investigation may have significant implications not only for Surgery Partners but for the broader arena of investor relations in publicly traded companies. As investors navigate these complexities, the importance of transparency and ethical corporate governance has never been more paramount.
This case exemplifies just how important it is for investors to remain informed and proactive about their investments, especially when financial forecasts appear grim. As the situation unfolds, stakeholders will undoubtedly be watching closely to see how Surgery Partners and its executives respond to these challenges, and whether they take the necessary steps to restore investor confidence in their operations again.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.